Navigation Links
Avandia Lawsuit Settlement News: 'No News is Bad News,' Says Plaintiffs
Date:4/5/2011

NEW YORK, April 5, 2011 /PRNewswire/ -- The latest news on the much publicized Avandia Settlement's is: there is no news.  After a Bloomberg report made public last summer that many of the Avandia suits were coming to a settlement range of approximately $86,000.00 per suit, no new news has come into the market.  This has left many suffering Avandia plaintiffs with more confusion -and concern- when they will actually get their settlement money.

This has led to many Avandia Plaintiffs to seek lawsuit funding in order to receive some cash to pay bills today, prior to getting their actual settlements.  Once industry that tracks the Avandia litigation is the "legal funding industry," where in March one funding company, lawsuitssettlementfunding.com (Legal-Bay LLC), announced a substantial rise in Avandia lawsuit cash advances.  

Dave Kole, CEO of Lawsuitssettlementfunding.com, spoke about the recent developments, "most of our clients tell us the same thing, they are frustrated with the process.  They are confused because there has been no news in the marketplace about how much they will receive, or worse, when they will actually receive their money.  Many of them were notified that they would have answers by the end of the first quarter, but now that we are in April, they simply can't wait any longer.  I only expect more and more Avandia Plaintiffs to seek lawsuit funding each day this drags on."  

Industry experts believe that the Avandia litigation is getting more complex based on the few articles released of late.  

In January GlaxoSmithKline agreed to take a total of a $3.4bil charge on the expected Avandia settlement.  This is an increase from the $2.4bil charge announced last summer.  The increase raises more questions as to the magnitude of the total settlement; and if Avandia will surpass Vioxx as the largest Pharmaceutical settlement in U.S. History.

Also, in February the Louisiana AG Office sued GlaxoSmithKline for civil fraud involving Avandia.  The increase in more litigation involving Avandia –and the subsequent delays- is now only hurting the people most affected by the drug.  And that is the Avandia long suffering plaintiffs and their families waiting for their settlement money.

Contact and Source:
CNJ Enterprises LLC
Chris Janish, CEO
862-485-7655
Email:  cnjenterprisesllc@gmail.com


'/>"/>
SOURCE CNJ Enterprises LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DePuy Hip Recall & Avandia Focus of Nov. 3 Conference, HB Announces
2. GSK Regulatory Update on Avandia Following EMA and FDA Reviews
3. American Heart Association Comment: Advisory Committee Recommends that U.S. Food and Drug Administration Keep Rosiglitazone (Avandia) on the Market, Continue Clinical Trial of Safety and Efficacy
4. GlaxoSmithKline Statement in Response to FDA Advisory Committees Vote on Safety of Avandia® (rosiglitazone)
5. GlaxoSmithKline Responds to US Senate Committee on Finance Report on Avandia
6. Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines
7. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
8. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
9. Two Large, Independent Outcomes Trials Offer New Important Safety Information on Cardiovascular Effects of AVANDIA(R)
10. MultiVu Video Feed: Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA
11. Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... 21, 2017 Mass Spectrometer Market: Overview ... This report on mass spectrometer ... prospects of the market globally. The stakeholders of ... the manufacture and commercialization of various mass spectrometer ... planning to enter this market. This report comprises ...
(Date:2/21/2017)... -- Luminex Corporation (NASDAQ: LMNX ) (the "Company") today ... of a quarterly cash dividend to its shareholders, the first ... payable on April 14, 2017 to shareholders of record as ... The board of directors intends for the Company ... holders of its common stock, representing a planned annual dividend ...
(Date:2/21/2017)... Feb. 21, 2017  Global health services company Cigna ... ® for breast reconstruction surgery and Dermacell ... an advanced acellular dermal matrix developed by LifeNet Health ... NVDQ ) "We are proud ... health-care payers to review the growing base of evidentiary ...
Breaking Medicine Technology:
(Date:2/21/2017)... Marne, Michigan (PRWEB) , ... February 21, 2017 ... ... contributions to the United States during Black History Month (officially African American ... additions to many fields of American society of a diverse race of people, ...
(Date:2/21/2017)... ... 21, 2017 , ... CLICKco LLC, a company dedicated to ... now available for purchase on RonnieColemanNutrition.com, a popular website for health and nutritional ... consumers who love coffee but are looking to add more protein to their ...
(Date:2/20/2017)... Boca Raton, FL (PRWEB) , ... February 20, ... ... for creating a patent-pending probiotic supplement that supports the proper levels of “good” ... for purchase on StackedNutrition.com, a popular nutritional products website. , Daily Body ...
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... ... and check-in, a cloud-based self-service technology that runs on the Posiflex XT-series of ... No. 1076 during HIMSS17 in Orlando, Florida. The terminal provider Posiflex ...
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... ReportingMD, a Population Health Software Company, is ... of the company. The new location will triple the size of the previous location ... the town of Sunapee, NH. , “We are excited to expand our footprint ...
Breaking Medicine News(10 mins):